PrimeGen US, Inc. (“PrimeGen US” or the “Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, announces it has entered into a definitive business combination agreement dated as of February 2, 2026 (the “Business Combination Agreement”) with DT Cloud Star Acquisition Corporation (“DT Cloud Star”), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an equity value for PrimeGen US of approximately $1.5 billion. PrimeGen US is a regenerative medicine company, leveraging nearly two decades of proprietary stem cell research to develop Triple Activated Mesenchymal Stem Cells (MSCs) as a novel, cell-based treatment for acute liver injury and related critical conditions.
Read the full article: PrimeGen US, Inc. Announces Proposed Business Combination with DT Cloud Star Acquisition Corporation //
Source: https://www.prnewswire.com/news-releases/primegen-us-inc-announces-proposed-business-combination-with-dt-cloud-star-acquisition-corporation-at-an-implied-equity-value-of-approximately-1-5-billion-to-advance-its-stem-cell-research-and-development-efforts-302678585.html